All lobbying filings

Avenue Solutions

Avenue Solutions filed a Q3 report for Genentech USA, Inc. on October 20, 2025, reporting $50,000 in lobbying income.

Lobbying for Genentech USA, Inc. · Biotechnology

As filed: AVENUE SOLUTIONS for GENENTECH USA, INC.

All filings by Avenue Solutions · Everything Genentech USA, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to 340b drug pricing program; Expiring healthcare extenders

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.